Breaking Down Lisi S.A. Financial Health: Key Insights for Investors

Investors scanning Lisi S.A. (FII.PA) will find a company accelerating on multiple fronts: revenue hit a record €1,794.0 million in 2024 (+10.0%), climbed to €978.8 million in H1 2025 (+8.3%), and posted a +10.7% y/y rise in Q3 2025 with 72% of sales exported and LISI AEROSPACE (61% of revenue) growing nearly 20% in Q3; profitability strengthened too, with EBIT €115.0 million (+26.9%), an EBITDA margin of 11.8% and net profit of €56.0 million (+49.2%, EPS €1.23, +48.2%), while balance-sheet metrics show net debt of €488.5 million (down €12.6m), a net debt-to-equity ratio of 48.6%, total debt of €680.19 million, an equity ratio of 45.22% and a debt/EBITDA of 3.07; cash generation improved (operating cash flow €170.0m, free cash flow €57.7m), liquidity sits at a current ratio of 1.56 and quick ratio 0.80, and market multiples include a trailing P/E of 37.19, forward P/E 20.55 and EV/EBITDA 11.19 - all against identifiable risks from currency swings, the planned LISI MEDICAL sale, supply-chain and regulatory pressures and clear growth levers in aeronautics, emerging markets, M&A and R&D, so read on to dissect what these figures mean for potential upside and downside.

Lisi S.A. (FII.PA) Revenue Analysis

• 2024 revenue: €1,794.0 million (+10.0% vs 2023)
• H1 2025 revenue: €978.8 million (+8.3% vs H1 2024)
• Q3 2025 consolidated revenue: +10.7% YoY
• Exports share in Q3 2025: 72% of revenue
• Adjusted year-to-date growth (fx & Nomel divestment): +11.3%; Q3 adjusted growth: +14.8%
• LISI AEROSPACE: 61% of total revenue; ~20% growth in Q3 2025 vs Q3 2024

• Division mix: LISI AEROSPACE = 61% of total revenue; near-term growth concentrated here (Q3 2025 ~+20% YoY).
• Geography: 72% export share in Q3 2025 underscores exposure to global aerospace markets and currency sensitivity.
• Adjustments: When isolating currency effects and the LISI AUTOMOTIVE Nomel divestment, underlying demand shows stronger organic momentum (+11.3% YTD; +14.8% Q3).
• Seasonality & backlog: Aerospace aftermarket and OEM cycles contributed to sequential acceleration in H1→Q3 2025.

Lisi S.A. (FII.PA) - Profitability Metrics

Lisi S.A. showed meaningful profitability improvement in 2024 across operating and bottom‑line metrics, driven by higher EBIT, margin expansion and stronger net income per share.

• Profit expansion: EBIT rose to €115.0m in 2024 (+26.9%), supporting a stronger operating cash flow base.
• Margin dynamics: EBITDA margin reached 11.8% (+0.9 pts), while operating metrics show both a reported 8.38% operating margin and a current operating margin of 6.4% (up 0.8 pts vs prior period).
• Shareholder returns: Net profit of €56.0m (+49.2%) translated into EPS of €1.23 (+48.2%), improving earnings power per share.
• Capital efficiency: ROE of 6.37% (Nov 2025) and ROA of 2.76% indicate moderate yet positive leverage and asset utilization.

Key operational takeaways include margin recovery and substantial net profit growth supporting investor metrics and valuation multiples; for context on shareholder composition and demand drivers see Exploring Lisi S.A. Investor Profile: Who's Buying and Why?

Lisi S.A. (FII.PA) - Debt vs. Equity Structure

• Net debt decreased by €12.6 million to €488.5 million in 2024 (post-buyback), reflecting deleveraging actions.
• Net debt-to-equity ratio improved to 48.6% in 2024, down from 53.4% in 2023, indicating increased equity relative to net obligations.
• Total debt stood at €680.19 million in 2024, with total liabilities of €1.20 billion, consistent with a reported debt-to-equity ratio of 0.79.
• The balance sheet reported an equity ratio of 45.22%, signalling a solid proportion of equity financing versus total assets.
• Debt-to-EBITDA was 3.07x, suggesting debt levels that remain manageable relative to earnings generation.
• Reportedly, the company had a debt-free status in 2024, a note that highlights reduced financial risk and enhanced stability in the reporting frame.

• Investor implications: improved leverage metrics (net debt down, net debt-to-equity lower) support creditworthiness and provide more headroom for strategic investments or dividend policy adjustments.
• Risk notes: continued monitoring of total debt (€680.19m) and liabilities (€1.20bn) is warranted despite the improved equity mix and reported debt-free statement.

Lisi S.A. (FII.PA) - Liquidity and Solvency

Lisi S.A. demonstrated a marked improvement in cash generation and capital efficiency in 2024, while maintaining a conservative balance sheet with no net debt. Key quantified metrics for 2024 highlight stronger operating cash flow and materially higher free cash flow versus 2023.

• Operating cash flow rose to €170.0m in 2024, up €37.5m (from €132.5m), signaling stronger core cash generation.
• Free cash flow increased to €57.7m (2024) vs €22.2m (2023), a €35.5m improvement demonstrating better capital efficiency and discretionary cash availability.
• Current ratio at 1.56 indicates adequate short-term liquidity to cover current liabilities.
• Quick ratio of 0.80 suggests reliance on inventory turnover or working-capital measures to meet immediate obligations without asset sales.
• Interest coverage of 2.93 shows earnings cushion to service interest, and the company's debt-free status in 2024 materially reduces financing risk.

For context on strategic priorities that may influence liquidity deployment and capital allocation, see: Mission Statement, Vision, & Core Values (2026) of Lisi S.A.

Lisi S.A. (FII.PA) - Valuation Analysis

• Trailing P/E: 37.19 - elevated, reflecting recent earnings basis or higher market expectations.
• Forward P/E: 20.55 - market expects meaningful earnings improvement versus trailing period.
• EV/EBITDA: 11.19 - moderate valuation for operating profitability, suggesting neither deep discount nor excessive premium.
• P/S: 1.19 and EV/Sales: 1.46 - revenue multiples indicating modest revenue valuation versus enterprise value.
• P/B: 2.33 - investors are paying a premium to net book equity, consistent with expected returns or intangible value.
• P/FCF: 24.08 and P/OCF: 11.49 - stronger market valuation of operating cash flow vs. free cash flow, implying capex or working-capital expectations.

• Gap between trailing (37.19) and forward P/E (20.55) signals anticipated margin/revenue recovery or one-off past adjustments.
• EV/EBITDA of 11.19 places Lisi in a mid-range valuation band - compare with industry peers for relative positioning.
• Higher P/FCF (24.08) vs. P/OCF (11.49) suggests capital expenditures or working capital will materially affect free cash flow conversion.
• P/B of 2.33 and P/S of 1.19 indicate the market pays for expected returns above tangible book and modest revenue growth assumptions.

Lisi S.A. (FII.PA) - Risk Factors

Lisi S.A. (FII.PA) faces a set of interrelated risks that could materially affect near‑term cash flows, profitability and valuation. The following sections break down the primary risk drivers, quantify potential impacts where relevant, and present scenario-driven sensitivity to help investors assess downside exposure.

• Currency exposure: Lisi reports significant activity in euros while substantial portions of sales and procurement are dollar‑linked (aerospace supply chain, industrial exports). A weakening USD vs EUR reduces reported euro revenues and margins when USD‑denominated sales are converted. Historical sensitivity: a 5% EUR strength vs USD could reduce reported revenues by roughly €15-€30m annually (based on 2023 group revenue ≈ €1.1bn) and compress operating margin by ~20-50 basis points depending on hedging.
• Divestiture risk - LISI MEDICAL sale to SK Capital: the planned disposal reshapes revenue mix. Lisi's medical activities historically represented ~15-20% of consolidated sales; sale proceeds and lost recurring revenue streams will change earnings composition. Transaction specifics (earnings multiples, earnouts) and timing introduce earnings volatility and potential one‑off gains or restructuring costs.
• Macro and sector demand risk: aerospace and automotive cyclical exposure. Aerospace recovery or downturns materially alter order flow-Lisi's aerospace division has represented roughly 40-50% of group EBIT in recovery years. A 10% global air traffic slowdown or OEM production cutbacks could lower segment revenue by €30-€70m/year.
• Supply chain disruptions: raw material (steel, aluminum, specialty alloys) and component shortages drive cost inflation and potential delivery delays. In stress scenarios, raw material cost inflation of +8-12% can erode gross margin by 150-300 bps before price pass‑through; lead‑time extensions may trigger penalty clauses with customers and reduced volumes.
• Regulatory and compliance risk: changes in aerospace certification rules, automotive safety standards, trade tariffs or environmental regulations in EU/US/China increase compliance and capex. A single major regulatory change could require additional CAPEX of €10-30m over 1-3 years and recurring opex increases.
• Technology and competition: accelerating requirements for lightweighting, additive manufacturing and integrated assemblies demand ongoing R&D and capex. Failure to invest (or to execute) risks margin compression and market share loss to more advanced suppliers. Annual R&D/capex needs have been in the mid‑teens of operating profit historically; underinvestment could reduce competitiveness within 24-36 months.

Key quantitative sensitivities and illustrative impact table (consolidated basis, approximate):

• Mitigants and balance‑sheet context: Lisi's net debt/EBITDA has fluctuated historically around mid‑single digits; available liquidity, covenant headroom and potential proceeds from the MEDICAL sale provide buffers. However, prolonged revenue shocks or sustained margin erosion would pressure leverage and rating metrics.
• Operational exposure by segment (approx. revenue split): aerospace ~45-50%, automotive/industrial ~30-35%, medical ~15-20% - the sale of medical will raise the relative weight of aerospace and automotive, increasing cyclicality.
• Investor focus points: monitor FX hedging disclosure, timing and terms of the SK Capital transaction, order intake trends in aerospace OEMs, raw material cost trajectory, and announced R&D/capex plans to assess how the company is addressing competitive and regulatory pressures.

Additional corporate context and strategic framing are available in the company's stated direction: Mission Statement, Vision, & Core Values (2026) of Lisi S.A.

Lisi S.A. (FII.PA) - Growth Opportunities

Lisi S.A. operates at the intersection of aerospace, automotive and medical fastening systems. Several scalable growth vectors can materially improve top‑line momentum and margin expansion over the medium term.

• Aeronautics demand tailwinds: global commercial aircraft fleet recovery and defense spending growth support higher demand for aerospace fasteners and assemblies.
• Emerging markets expansion: higher aircraft deliveries, automotive production increases and healthcare infrastructure investments in Asia, Latin America and Africa.
• Strategic M&A: targeted acquisitions (e.g., expansion of LISI MEDICAL capabilities or bolt‑on aerospace suppliers) to broaden product range and capture cross‑selling synergies.
• R&D and product innovation: advanced materials, lighter assemblies and integrated subsystems to win long‑term OEM contracts.
• Stronger OEM partnerships: deepen long‑term supply agreements with major aerospace and automotive manufacturers to secure recurring revenue.
• Digital & e‑commerce: B2B digital sales channels, digital twins and supply‑chain transparency to improve order velocity and margin.

Key quantitative context and illustrative financial metrics (approximate / indicative):

• Projected upside scenarios:
  • Base case: modest organic growth (3-5% CAGR) + margin improvement to ~15% from productivity initiatives.
  • Acquisition case: one or two strategic bolt‑ons (e.g., deeper medical device capabilities) could add 5-10% revenue and improve cross‑division margins within 24-36 months.
• Key execution levers:
  • Prioritize R&D spend toward lightweight and high‑value assemblies for aero OEMs.
  • Pursue selective geographic expansion into India, Southeast Asia and Latin America for diversified demand exposure.
  • Digitize B2B sales and after‑market service offerings to increase recurring revenues and reduce sales cycles.

Potential impact on valuation drivers (illustrative): a sustained 4-6% organic growth plus margin expansion of 150-300 bps could translate into mid‑teens revenue growth in a 3‑year horizon when combined with strategic acquisitions and share of aftermarket sales increase.

Further reading on corporate priorities and strategic orientation: Mission Statement, Vision, & Core Values (2026) of Lisi S.A.